Evidence map›Paper›PMID 31900274›Full record

ArticleBMJ open2020

Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial.

Greg J Fox, Cam Binh Nguyen, Thu Anh Nguyen, Phuong Thuy Tran, Ben J Marais, Steve M Graham, Binh Hoa Nguyen, Kavi Velen, David W Dowdy, Paul Mason and 6 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Pooled it
  2. Article
  3. Article
  4. Tuberculosis: An Update for the Clinician.Respirology (Carlton, Vic.) · 2025
    Review
  5. Article
  6. Review
  7. Tuberculosis prevention: current strategies and future directions.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2024
    Review
  8. Article
  9. The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. The cascade of care for household contacts of people with drug-resistant TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023
    Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 5 countries.

Greg J FoxCentral Clinical School, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia greg.fox@sydney.edu.au.ORCID 0000-0002-4085-1411
Cam Binh NguyenWoolcock Institute of Medical Research, Glebe, New South Wales, Australia.
Thu Anh NguyenWoolcock Institute of Medical Research, Glebe, New South Wales, Australia.
Phuong Thuy TranWoolcock Institute of Medical Research, Glebe, New South Wales, Australia.
Ben J MaraisThe University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia.
Steve M GrahamMurdoch Childrens Research Institute, Parkville, Victoria, Australia.
Binh Hoa NguyenThe National Lung Hospital, Hanoi, Vietnam.
Kavi VelenWoolcock Institute of Medical Research, Glebe, New South Wales, Australia.
David W DowdyDepartment of Epidemiology, John Hopkins Bloomberg, Baltimore, Maryland, USA.
Paul MasonTaronga Institute of Science and Learning, Taronga Conservation Society, Sydney, New South Wales, Australia.
Warwick J BrittonThe University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia.
Marcel A BehrDepartment of Medicine, McGill University, Montreal, Quebec, Canada.
Andrea BenedettiDepartments of Medicine and of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, Quebec, Canada.
Dick MenziesMcGill International Tuberculosis Centre, McGill University, Montreal, Quebec, Canada.
Viet Nhung NguyenThe National Lung Hospital, Hanoi, Vietnam.
Guy B MarksWoolcock Institute of Medical Research, Glebe, New South Wales, Australia.
The University of Sydney · AUWoolcock Institute of Medical Research · AUMcGill University · CAHanoi Lung Hospital · VNBloomberg (United States) · USTaronga Conservation Society Australia · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTreatment of latent tuberculosis infection (LTBI) plays a substantial role in the prevention of drug-susceptible tuberculosis (TB). However, clinical trials to evaluate the efficacy of preventive therapy for presumed multidrug-resistant (MDR) LTBI are lacking. This trial aims to evaluate the efficacy of the antibiotic levofloxacin in preventing the development of active TB among latently infected contacts of index patients with MDR-TB. METHODS AND ANALYSIS: A double-blind placebo-controlled parallel group randomised controlled trial will be conducted in 10 provinces of Vietnam. Household contacts living with patients with bacteriologically confirmed rifampicin-resistant or MDR-TB will be eligible for recruitment if they have a positive tuberculin skin test or are known to be immunosuppressed, and do not have active TB. Participants will be randomised to receive either levofloxacin or placebo tablets once per day for 6 months. Screening for incident TB will be performed at 6 months intervals. The primary study outcome is the incidence of bacteriologically confirmed TB within 30 months after randomisation. Analysis will be by intention to treat, using Poisson regression. ETHICS: Ethical approval from the University of Sydney Human Research Ethics Committee was obtained on 29 April 2015 (2014/929), and from the Vietnam Ministry of Health Institutional Review Board on 30 September 2015 (4040/QD-BYT). DISSEMINATION: Findings of the study will be published in peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER: ACTRN12616000215426.

Indexed as

AdolescentAdultAnti-Bacterial AgentsChildDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesHumansIncidenceLatent TuberculosisLevofloxacinMaleMulticenter Studies as TopicRandomized Controlled Trials as TopicTreatment OutcomeAnti-Bacterial AgentsLevofloxacinlatent tuberculosis tuberculosis, multidrug-resistant mycobacterium tuberculosis fluoroquinolonestherapeutic use humans clinical trial protocoltherapeutic use levofloxacin

Identifiers

PMID31900274
PMCPMC6955503
OpenAlexW2998262099

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.